A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC

Jonasch, Eric; Hauke, Ralph; Falchook, Gerald; Logan, Theodore; Gordon, Michael; Hall, Evan; Schuch, Brian; Bilen, Mehmet A; Naqash, Abdul; Zakaharia, Yousef; Ryan, Christopher W; Lally, Satwant; Xiao, Jim; Zimmerman, Zachary; Srinivasan, Ramaprasad; Choueiri, Toni K

doi:10.1093/oncolo/oyad216.019

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC

Background: Inactivation of the VHL gene leading to aberrant HIF2α activity is nearly universal in clear cell renal cell carcinoma (ccRCC). NKT2152 is a novel, potent, selective orally available HIF2α inhibitor optimized for enhanced PK exposure and sustained target inhibition which has demonstra…